Credits: Canva
The US Food and Drug Administration has approved TNKase or Tenecteplase, which is a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
Ischemic strokes happen when a blood clot blocks a blood vessel in your brain. It can cause permanent brain damage and death. If enough brain cells die, you can also lose the abilities or body functions those cells control. They are also the most common types of stroke, with 80% of all strokes being ischemic strokes.
It is delivered as a single five-second intravenous bolus, which is faster than the standard of care Activase or alteplase, which is administered as an intravenous bolus followed by a 60-minute infusion. The manufacturer of TNKase, Genetech said a new 25-mg vial configuration will also be available in the coming months.
The approval came at the backdrop of a study that compared TNKase to Activase in patients with acute ischemic stroke. These patients also presented with a disabling neurological deficit. Results show that TNKase was comparable to Activase in terms of efficacy and safety.
In the United States it self, it affects more than 795,000 people each year and is the leading cause of long-term disability. It is also the fifth leading cause of death. Since brain damage can happen if this progresses rapidly, one needs an immediate, fast-acting medical care.
TNKase thus provide a faster and simpler administration which can be critical for anyone. The chief medical officer and head of global product development at Genetech, Levi Garraway, MD., PhD., said, "Today's approval is a significant step forward and underscores our commitment to advancing stroke treatment options for patients."
Some of the most common symptoms include weakness or paralysis on one side of your face and body. You may also feel trouble speaking or have loss of speech, also known as aphasia. You may faced slurred or garbled speaking, also known as dysarthria. Other symptoms include loss of muscle control on one side of your face, or sudden worsening or loss of your senses, including vision, hearing, smell, taste, and touch.
While these are symptoms one has who is prone to this condition. However, often, many may confuse it with other illnesses. It is best to keep an eye out for warning signs. These could be looking out for yourself or your loved one. Note if there is a sudden loss of balance. Look out for sudden vision loss or changes in one or both eyes. Look for a droop on one or both sides of your face, especially when you smile. Raise both arms and see if one arm sags or drops in a way it usually does not. Note for your speech. Are you as fluent? Are you have trouble speaking? If you see any of such signs, start tracking it and talk to your healthcare provider.
Credit: JamPress
A 51-year-old Brazilian businesswoman has died after undergoing six facial cosmetic procedures during surgery lasting several hours.
Andreia Vieira Gaspar, from Goiânia, Brazil, died on August 12, the Daily Star reported.
According to Brazilian news outlet G1 Goiás, the procedures reportedly included a deep facelift, neck liposuction, eyelid surgery, jawline work and other facial procedures.
Andreia reportedly left the operating theatre heavily swollen and struggling to breathe. Her condition worsened overnight, with neck pain and increasing breathing difficulties. She reportedly told her sister, Djiane Vieira: “Sis, I'm dying.”
Djiane then sought help from the medical team through a group chat, saying her sister was dying and asking for immediate assistance.
The Public Ministry of Goiás has requested a police investigation into possible involuntary manslaughter.
The family alleged that Andreia's condition worsened after surgery and questioned whether the hospital was equipped to handle a serious postoperative emergency. They also alleged that it did not have an intensive care unit or an ambulance available.
G1 reported that her condition deteriorated about six hours after surgery and that she died despite resuscitation attempts.
A medical report cited by the family identified acute thrombosis and pulmonary infarction as the causes of death.
Andreia had previously run a beauty salon in Goiânia and had lived in Spain for five years. Her family said undergoing the procedures had been a long-held dream. Her sister said Andreia had spent two years saving for the surgery, which cost BRL 118,000 (£16,800).
Social media trends, celebrity endorsements and demand for anti-ageing treatments have fueled interest in cosmetic procedures and injectable treatments. Experts warn that unregulated procedures can carry risks, including allergic reactions and infections, while severe complications can affect organs such as the liver and kidneys.
The cosmetic surgery market was estimated at USD 94.1 billion in 2025.
Experts stress that cosmetic procedures should involve realistic expectations, qualified medical advice and a clear understanding of the risks, recovery and costs.
Dr Chintan Gujarati, Cosmetic and Plastic Surgeon at Ruby Hall Clinic, told HealthandMe that cosmetic procedures require careful planning and informed decision-making.
He recommends asking:
1. Is the procedure right for me?
Discuss whether it suits your health, goals and individual needs.
2. Is my surgeon qualified?
Ensure the procedure is performed by a board-certified plastic surgeon or appropriately trained specialist.
3. What are the risks?
Ask about possible complications, including infection, scarring and the need for further treatment.
4. What results can I realistically expect?
Cosmetic procedures can improve appearance but cannot guarantee perfection.
5. What is the recovery process?
Ask about downtime, pain management, activity restrictions and when you can resume normal activities.
6. What will the procedure cost?
Request a breakdown of consultation, hospital, medication and follow-up costs.
7. What if I am unhappy with the results?
Discuss revision policies and corrective options before proceeding.
Credit: iStock
Children under 15 account for half of the 46 suspected mpox cases in Guinea-Bissau, which declared its first mpox outbreak on July 4, UNICEF said.
As of August 17, the country had reported seven confirmed cases, all among adults. Six were reported in the Autonomous Sector of Bissau and one in the Biombo Region. No deaths have been reported.
Of the 46 suspected cases, 23 are children under 15, including 16 aged 0-4 years. Young children face a greater risk of complications from mpox.
“This is the first time mpox cases have been reported in Guinea-Bissau, making even a small outbreak a major public health event,” said Sandra Martins, UNICEF Deputy Representative in Guinea-Bissau.
“While the country’s surveillance system remains extremely fragile, we face the risk that cases are going undetected, particularly among children who are the most vulnerable to severe complications.”
UNICEF said the confirmed cases do not appear connected, raising concerns about undetected chains of transmission and additional unidentified cases.
Gaps remain in community-based surveillance, including contact identification, sample testing and tracing how the virus is spreading.
Martins urged families to seek care if a child or family member develops a rash, fever, swollen lymph nodes or other symptoms.
Mpox is a viral zoonotic disease that can spread from animals to humans. It is caused by the monkeypox virus, part of the Orthopoxvirus genus, the same family as the variola virus that causes smallpox.
Mpox symptoms are generally milder than those of smallpox. After an incubation period of 5 to 21 days, symptoms typically begin with fever, headache, muscle aches and fatigue.
The disease usually resolves within 2 to 4 weeks, but severe cases can occur, particularly in children, pregnant women and immunocompromised people. Common symptoms include:
Mpox can spread through direct contact with the blood, bodily fluids or skin lesions of infected animals, including rodents and primates.
Human-to-human transmission can occur through close contact with respiratory secretions, skin lesions or contaminated objects. The virus can enter through broken skin, the respiratory tract or the mucous membranes of the eyes, nose or mouth.
The World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) guidelines for preventing mpox transmission include:
Credit: AI
The Centre has tightened restrictions on certain cough and cold medicines for children below four years, citing potential health risks associated with a specific drug combination in children.
The Union Health Ministry has restricted the manufacture, sale and distribution of fixed-dose combinations (FDCs) containing chlorpheniramine maleate and phenylephrine hydrochloride for children under four.
Manufacturers have also been instructed to carry a clear warning stating that the medicine “shall not be used in children below four years of age.”
The decision follows recommendations from an expert committee and the Drugs Technical Advisory Board (DTAB), which reviewed the safety of the combination in young children.
Chlorpheniramine is an antihistamine, while phenylephrine is a decongestant. The combination is used to relieve symptoms like blocked or runny nose, sneezing and watery eyes caused by colds, flu and allergies.
However, young children can respond differently to medicines than adults, and dosing errors or adverse effects can result in more serious effects in this age group.
The Health Ministry’s expert committee concluded that the combination could pose potential health risks in children below four, particularly when safer alternatives are available.
The latest directive therefore requires manufacturers to clearly communicate the age restriction rather than putting the onus on parents.
A common cold is usually caused by a virus, meaning antibiotics do not treat it. In many children, symptoms improve with supportive care such as adequate fluids, rest and measures recommended by a paediatrician.
Combination cough and cold products can contain several active ingredients, increasing the possibility of incorrect dosing and side effects if parents give more than one medicine containing the same ingredient.
This is particularly important for young children because their medication doses are generally calculated according to age and/or body weight.
The government has been tightening oversight of paediatric medicines following serious concerns surrounding cough syrups in India.
In June, the Centre removed cough syrups from an exemption that had allowed certain products to be sold through retail outlets in smaller villages without the same pharmacy restrictions.
Parents should avoid giving children under four any medicine containing this combination unless specifically advised by a qualified healthcare professional.
The government has emphasised that safer alternatives are available, while the latest restriction is intended to reduce avoidable medication-related risks in young children.
© 2024 Bennett, Coleman & Company Limited